6533b851fe1ef96bd12a8e8d
RESEARCH PRODUCT
Matrix metalloproteinase-12 cleaved fragment of titin as a predictor of functional capacity in patients with heart failure and preserved ejection fraction
Patricia PalauJuan SanchisL. LopezJosé María RamónEloy DomínguezAlexander Lynge Reese-petersenAnna MollarFrancisco J. ChorroJulio Núñezsubject
Maleanimal structuresfunctional capacity030204 cardiovascular system & hematologyMatrix (biology)Matrix metalloproteinase03 medical and health sciences0302 clinical medicineMatrix Metalloproteinase 12HumansMedicineConnectin030212 general & internal medicineExerciseAgedAged 80 and overHeart FailureEjection fractionbiologybusiness.industryStroke Volumetitin degradationmusculoskeletal systemmedicine.diseaseMolecular biologyheartfailure with preservedejection fractionHeart failureembryonic structuresCirculatory systemcardiovascular systembiology.proteinBiomarker (medicine)FemaleTitinCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractiontissuesBiomarkersdescription
Serum levels of matrix metalloproteinase-12 cleaved fragment of titin (TIM), a novel circulatory biomarker specific for cardiac titin degradation, has emerged as a potential biomarker in cardiovascular diseases. In this work, we aimed to evaluate the association between TIM and maximal functional capacity assessed by the percentage of predicted peak exercise oxygen uptake (pp-peakVO2) in patients with heart failure and preserved ejection fraction (HFpEF). Design. In this post-hoc study, we included 46 stable symptomatic (New York Heart Association II-III) HFpEF patients enrolled in the TRAINING-HF study (NCT02638961). pp-peak-VO2 was calculated from baseline values. Baseline circulating levels of TIM were measured by competitive ELISA in serum from the TRAINING-HF patients. The independent association between TIM and pp-peakVO2 was evaluated by multivariate linear regression analysis. Results. The mean age of the sample was 73.8 ± 8.7 years, 56.5% were females, and 76.1% were on NYHA II. The medians of pp-peakVO2 and TIM were 60.9% (50.4–69.3), and 130.1 ng/mL (98.1–159.5), respectively. The median of NT-proBNP was 912 pg/mL (302–1826). pp-peakVO2 was significant and inversely correlated with TIM (r= −41, p = .005). In multivariate analysis, after adjusting for NYHA class, hypertension, body mass index, and glomerular filtration rate, higher TIM was significantly associated with lower pp-peak VO2 (p = .029). Conclusions. In this sample of stable and symptomatic HFpEF patients, higher serum levels of TIM identified patients with worse functional status.
year | journal | country | edition | language |
---|---|---|---|---|
2020-01-01 |